Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Currently, a significant percentage of patients with DLBCL are refractory or relapse after a first line of immunochemotherapy. Second relapses after autologous stem cell transplantation or chimeric antigen receptor T-cell therapies present few treatment options and do not yield good results. New mol...
Saved in:
Published in | International journal of molecular sciences Vol. 25; no. 14; p. 7580 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
MDPI AG
01.07.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!